Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Localized Prostate Cancer × padeliporfin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma 5 Urogenital Neoplasms 4 Prostatic Neoplasms 4 Prostatic Diseases 4 Neoplasms by Site 4 Neoplasms 4 Male Urogenital Diseases 4 Genital Neoplasms, Male 4 Genital Diseases, Male 3 Transitional Cell Cancer of Renal Pelvis and Ureter 1 Lung Neoplasms 1 Localized Prostate Cancer 1 Genital Diseases 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

padeliporfin 1 Tablets 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

Phase 2 Active not recruiting

50 enrolled 8 charts

Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡